13 September 2019 in Epidemiology and Vaccinal Prevention
Relevance.Bronchial asthma is widespread in the world, according to WHO estimates, 235 million people suffer from it. In Russia, according to official figures, 1.3 million cases of bronchial asthma have been reported. Domestic experts reasonably believe that these data are underestimated at least 4 times. Considering that patients with bronchial asthma undergo significant changes in the immune system and are especially difficult to tolerate respiratory and other infectious diseases, determining the effect of vaccination on the clinical course of bronchial asthma is very important. The purpose of the review is to show how vaccinations against pneumococcal infection and influenza affect the condition of patients with bronchial asthma.Conclusion.Features of formation of protective immunity at various schemes of immunization against pneumococcal infection are analyzed. In patients with bronchial asthma, the justification of the vaccination scheme with the advantage of the priority administration of conjugated polysaccharide vaccine with the subsequent introduction of a polysaccharide pneumococcal vaccine after 8 weeks is given. Vaccination against pneumococcal infections has led to the elimination of sputum S. рneumoniae. In vaccination against pneumococcal infection, there was an improvement in the level of disease control, which was confirmed by the ACQ-5 test-a decrease in the indicator from 2 [1,5;1,8;3] points (lack of asthma control) to 0,6 [0;1] points (asthma control) during the year of observation, p < 0,001. Vaccination against influenza in patients with bronchial asthma leads to a decrease in the frequency and duration of exacerbations, there is a decrease in the level of markers of systemic inflammation. Combined vaccination against influenza and pneumococcal infection is not accompanied by a reliable difference in tolerability in comparison with monovaccination only against pneumococcal infection or influenza.
3 May 2024 in Epidemiology and Vaccinal Prevention
The considerable success of vaccination against the new coronavirus infection, which has led to a decrease in morbidity and mortality in adults and children, requires the study of the problem of revaccination against SARS-CoV-2. The pathogenic properties of the virus and its unpredictable mutations continue to support an unfavorable epidemic situation in different regions of the world. Revaccination regimens against SARS-CoV-2 are being developed in different countries and populations based on epidemiological indications. The issue of introducing vaccination against a new coronavirus infection into national vaccination calendars for adults and children is debatable and requires further study.
10 September 2024 in Medical Bulletin of the Ministry of Internal Affairs
The paper considers the issues of revaccination of the adolescents against pertussis, dynamics of total IgE and antipertussis antibodies levels in revaccinated children aged 14, as well as development of local and systemic reactions.
30 March 2026 in Acta medica Eurasica
The article is devoted to an urgent problem of practical medicine – secondary immunodeficiencies. In the practice of a primary care physician of any specialty, patients with secondary immunodeficiencies are much more common than those with primary immunodeficiency, but they are extremely rarely diagnosed. To date, there is no official diagnosis "secondary immunodeficiency", which explains why this condition is underdiagnosed and why there are no standardized approaches to its treatment. Secondary immunodeficiencies are known to develop in individuals whose immune systems were initially functioning normally and can manifest at any age. An important clinical sign of secondary immunodeficiency is an increased susceptibility to infectious diseases, caused by a reduction in the number and/or functional activity of immune system cells. Secondary immunodeficiencies most commonly manifest by respiratory diseases affecting the upper respiratory tract, formation of foci of chronic infection: nasopharyngitis, rhinosinusitis, otitis media, tonsillitis. Viral infections mainly inhibit the cellular component of the immune system, reducing the activity of CD4-lymphocytes, and cause an imbalance of cytokines. Frequent, sometimes unjustified prescribing of antibiotics leads to disruption of the intestinal microflora, which can worsen the course of secondary immunodeficiency. The article examines the main causes of secondary immunodeficiency, clinical classification and general approaches to patient management. The importance of a clinical and laboratory examination to clarify the affected link of immunity is shown. As part of the patient’s treatment, immunological parameters and the results of microbiological stool tests were analyzed. A clinical case of a patient with secondary immunodeficiency is described, demonstrating the effectiveness of therapy using bacteriophages.
25 October 2024 in Russian Journal of Immunology
Novel coronavirus infection requires analyzing its course in patients with allergic diseases. Patients with atopic allergic diseases remain insufficiently studied with regard to the peculiarities of the course of both the underlying allergic disease and infectious processes caused by viruses and bacteria. Epithelial cells in bronchial asthma do not respond sufficiently to interferons, suggesting that SARS-CoV-2 infection may suppress spontaneous upregulation of angiotensin-converting enzyme expression, which ultimately reduces disease severity, but at the same time makes patients with allergic atopic diseases susceptible to other viral infections. The results obtained indicate statistically significant differences in the formation of anti-RBD IgG antibodies to SARS-CoV-2 between the group of adolescents with bronchial asthma vaccinated against a new coronavirus infection and those not vaccinated against it. During the follow-up period after 6 months, a statistically significant increase in anti-RBD IgG titer to SARS-CoV-2 due to novel coronavirus infection was observed among the unimmunized children. Clinical parameters indicated a favorable course of atopic process and control of bronchial asthma exacerbations in adolescents who received vaccination against both new coronavirus infection and influenza, while those who did not receive vaccination against these viral infections had bronchial asthma exacerbations due to respiratory infection. Also among patients with bronchial asthma who received influenza vaccination, there were no cases of influenza A and bronchial asthma exacerbations due to respiratory infections. In this regard, influenza vaccination is an important intervention to maintain control of asthma exacerbations. It is noteworthy that no new coronavirus infection was reported among vaccinated adolescents within a year after immunization. At the same time, 6 months after vaccination against a new coronavirus infection, we observed a statistically significant increase in antibody levels in unvaccinated adolescents, indicating the presence of high viral neutralizing activity. Vaccination against novel coronavirus infection in patients with bronchial asthma may be considered a possibility.